DK3322701T3 - Ethynylderivater som metabotropiske glutamatreceptormodulatorer - Google Patents
Ethynylderivater som metabotropiske glutamatreceptormodulatorer Download PDFInfo
- Publication number
- DK3322701T3 DK3322701T3 DK16739442.8T DK16739442T DK3322701T3 DK 3322701 T3 DK3322701 T3 DK 3322701T3 DK 16739442 T DK16739442 T DK 16739442T DK 3322701 T3 DK3322701 T3 DK 3322701T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor modulators
- glutamate receptor
- metabotropic glutamate
- ethynyl derivatives
- ethynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15176854 | 2015-07-15 | ||
PCT/EP2016/066393 WO2017009275A1 (en) | 2015-07-15 | 2016-07-11 | Ethynyl derivatives as metabotropic glutamate receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3322701T3 true DK3322701T3 (da) | 2019-07-08 |
Family
ID=53758003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16739442.8T DK3322701T3 (da) | 2015-07-15 | 2016-07-11 | Ethynylderivater som metabotropiske glutamatreceptormodulatorer |
Country Status (30)
Country | Link |
---|---|
US (3) | US10189848B2 (da) |
EP (1) | EP3322701B1 (da) |
JP (1) | JP6761821B2 (da) |
KR (1) | KR20180026438A (da) |
CN (1) | CN107580598B (da) |
AR (1) | AR105341A1 (da) |
AU (1) | AU2016292863B2 (da) |
CA (1) | CA2984711C (da) |
CL (1) | CL2018000036A1 (da) |
CO (1) | CO2017011174A2 (da) |
CR (1) | CR20180022A (da) |
DK (1) | DK3322701T3 (da) |
ES (1) | ES2733468T3 (da) |
HR (1) | HRP20191139T1 (da) |
HU (1) | HUE045145T2 (da) |
IL (1) | IL255096B (da) |
LT (1) | LT3322701T (da) |
MA (1) | MA42442B1 (da) |
MX (1) | MX2018000592A (da) |
PE (1) | PE20180356A1 (da) |
PH (1) | PH12018500106A1 (da) |
PL (1) | PL3322701T3 (da) |
PT (1) | PT3322701T (da) |
RS (1) | RS58929B1 (da) |
RU (1) | RU2721776C9 (da) |
SI (1) | SI3322701T1 (da) |
TR (1) | TR201909160T4 (da) |
TW (1) | TWI612962B (da) |
UA (1) | UA120463C2 (da) |
WO (1) | WO2017009275A1 (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
DK2986610T5 (da) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | Bicykliske heterocykler som fgfr-inhibitorer |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
CN107580598B (zh) | 2015-07-15 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为代谢型谷氨酸受体调节剂的乙炔基衍生物 |
PE20190382A1 (es) | 2016-07-18 | 2019-03-08 | Hoffmann La Roche | Derivados etinilo |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
BR112021001131A2 (pt) | 2018-07-26 | 2021-04-20 | Domain Therapeutics | derivados de quinazolinona substituídos e seu uso como moduladores alostéricos positivos de mglur4 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
UA90145C2 (ru) | 2005-05-24 | 2010-04-12 | Лаборатуар Сероно С.А. | Трициклические спиро-производные как модуляторы crth2 |
CN101528711A (zh) | 2006-08-31 | 2009-09-09 | 先灵公司 | 可用作抗细菌剂的乙内酰脲衍生物 |
WO2008151184A1 (en) | 2007-06-03 | 2008-12-11 | Vanderbilt University | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
CA2952055C (en) | 2008-02-01 | 2020-07-21 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Monoclonal antibodies for ebola and marburg viruses |
WO2010081492A1 (en) | 2009-01-19 | 2010-07-22 | Fondazione Ospedale Maggiore Policlinico Mangiagalli Regina Elena - Milano | Melanocortin analogs with antimicrobial activity |
US9097713B2 (en) | 2009-09-02 | 2015-08-04 | The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc | Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus |
WO2011029104A1 (en) | 2009-09-04 | 2011-03-10 | Vanderbilt University | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US8389536B2 (en) | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US8586581B2 (en) | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
US8772300B2 (en) | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
HUE025031T2 (en) | 2011-04-26 | 2016-02-29 | Hoffmann La Roche | Ethinyl derivatives as positive allosteric modulators of MGLUR5 |
US10533000B2 (en) | 2011-05-26 | 2020-01-14 | Sunovion Pharmaceuticals, Inc. | Metabotrophic glutamate receptor 5 modulators and methods of use thereof |
US20130123254A1 (en) | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
NZ703537A (en) | 2012-10-18 | 2018-06-29 | Hoffmann La Roche | Ethynyl derivatives |
SG11201501375YA (en) | 2012-10-18 | 2015-03-30 | Hoffmann La Roche | Ethynyl derivatives as modulators of mglur5 receptor activity |
CN105121424B (zh) | 2013-02-18 | 2019-01-22 | 华领医药技术(上海)有限公司 | mGluR调节剂 |
UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
DK3049409T3 (da) * | 2013-09-25 | 2017-07-10 | Hoffmann La Roche | Ethynylderivater |
TWI649310B (zh) * | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
WO2015123777A1 (en) | 2014-02-19 | 2015-08-27 | Cangene Corporation | Methods of modulating an immune response |
CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
AU2015222303B2 (en) | 2014-02-25 | 2019-02-28 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
CN106999566B (zh) | 2014-10-03 | 2022-01-28 | 麻省理工学院 | 结合埃博拉病毒糖蛋白的抗体及其用途 |
WO2016146600A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | 3-(4-ethynylphenyl)hexahydropyrimidin-2,4-dione derivatives as modulators of mglur4 |
CN107580598B (zh) | 2015-07-15 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为代谢型谷氨酸受体调节剂的乙炔基衍生物 |
PE20190382A1 (es) | 2016-07-18 | 2019-03-08 | Hoffmann La Roche | Derivados etinilo |
-
2016
- 2016-07-11 CN CN201680026777.2A patent/CN107580598B/zh active Active
- 2016-07-11 CR CR20180022A patent/CR20180022A/es unknown
- 2016-07-11 LT LTEP16739442.8T patent/LT3322701T/lt unknown
- 2016-07-11 MX MX2018000592A patent/MX2018000592A/es active IP Right Grant
- 2016-07-11 PT PT16739442T patent/PT3322701T/pt unknown
- 2016-07-11 SI SI201630292T patent/SI3322701T1/sl unknown
- 2016-07-11 RS RS20190819A patent/RS58929B1/sr unknown
- 2016-07-11 ES ES16739442T patent/ES2733468T3/es active Active
- 2016-07-11 DK DK16739442.8T patent/DK3322701T3/da active
- 2016-07-11 PL PL16739442T patent/PL3322701T3/pl unknown
- 2016-07-11 JP JP2017564709A patent/JP6761821B2/ja active Active
- 2016-07-11 HU HUE16739442A patent/HUE045145T2/hu unknown
- 2016-07-11 CA CA2984711A patent/CA2984711C/en active Active
- 2016-07-11 PE PE2017002337A patent/PE20180356A1/es unknown
- 2016-07-11 EP EP16739442.8A patent/EP3322701B1/en active Active
- 2016-07-11 AU AU2016292863A patent/AU2016292863B2/en active Active
- 2016-07-11 TR TR2019/09160T patent/TR201909160T4/tr unknown
- 2016-07-11 RU RU2018103944A patent/RU2721776C9/ru active
- 2016-07-11 KR KR1020187000004A patent/KR20180026438A/ko not_active Application Discontinuation
- 2016-07-11 UA UAA201801133A patent/UA120463C2/uk unknown
- 2016-07-11 MA MA42442A patent/MA42442B1/fr unknown
- 2016-07-11 WO PCT/EP2016/066393 patent/WO2017009275A1/en active Application Filing
- 2016-07-13 AR ARP160102117A patent/AR105341A1/es unknown
- 2016-07-14 TW TW105122266A patent/TWI612962B/zh active
-
2017
- 2017-10-17 IL IL255096A patent/IL255096B/en active IP Right Grant
- 2017-10-30 CO CONC2017/0011174A patent/CO2017011174A2/es unknown
-
2018
- 2018-01-05 CL CL2018000036A patent/CL2018000036A1/es unknown
- 2018-01-12 US US15/869,268 patent/US10189848B2/en active Active
- 2018-01-12 PH PH12018500106A patent/PH12018500106A1/en unknown
- 2018-12-14 US US16/220,512 patent/US11034699B2/en active Active
-
2019
- 2019-06-21 HR HRP20191139TT patent/HRP20191139T1/hr unknown
-
2021
- 2021-05-09 US US17/315,349 patent/US20210269452A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3322701T3 (da) | Ethynylderivater som metabotropiske glutamatreceptormodulatorer | |
MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
DK3394033T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
DK3294713T3 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
DK3302448T3 (da) | Erstattede heterocyclylafledninger som cdk-inhibitore | |
DK3094631T3 (da) | Pyrimidinyloxybenzenderivater som herbicider | |
DK3490565T3 (da) | Azetidinderivater som chemokinreceptormodulatorer og anvendelser deraf | |
DK3359160T3 (da) | Farnesoid x receptor modulatorer | |
DK3131902T3 (da) | Forbindelser som ROR-gamma-modulatorer | |
DK3363790T3 (da) | 1,2,4-oxadiazolderivater som immunmodulatorer | |
DK3377483T3 (da) | N-substituerede indolderivater som pge2-receptormodulatorer | |
DK3313832T3 (da) | 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere | |
DK3539961T3 (da) | Polycykliske amidderivativer som cdk9-inhibitorer | |
DK3319963T3 (da) | Substituerede 4-azaindoler og deres anvendelse som glun2b receptormodulatorer | |
DK3625228T3 (da) | Pyrimidinderivater som pge2-receptormodulatorer | |
DK3153508T3 (da) | Naphthofuranderivater til anvendelse som anticancermidler | |
DK3625222T3 (da) | Phenylderivater som pge2-receptormodulatorer | |
DK3288940T3 (da) | Azabenzimidazoler og deres anvendelse som ampa-receptormodulatorer | |
DK3022174T3 (da) | Derivater af n-urinstof-substituerede aminosyrer som formylpeptidreceptormodulatorer | |
DK3672951T3 (da) | Quinoxalinderivater som adenosinreceptorantagonister | |
DK3490986T3 (da) | Piperidin-cxcr7-receptormodulatorer | |
DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
DK3265459T3 (da) | Amidforbindelser som 5-ht4-receptoragonister | |
DK3347349T3 (da) | Fluorindolderivater som muskarin m1-receptor-positive allosteriske modulatorer | |
DK3661941T3 (da) | Thiazolopyridinderivater som adenosinreceptor-antagonister |